Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22165847 | 0.83 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL14801604 | 0.77 | USP2 (0.36) | SLC6A2 | |
| SCHEMBL1979673 | 0.74 | MEN1 (0.30) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL927689 | 0.74 | — | — | |
| SCHEMBL27036887 | 0.73 | MEN1 (0.33) | MEN1HTTKMT2AL3MBTL1 | |
| SCHEMBL15285537 | 0.73 | DGAT1 (0.34) | — | |
| SCHEMBL29155913 | 0.72 | USP2 (0.33) | — | |
| SCHEMBL1982449 | 0.72 | — | — | |
| SCHEMBL1964999 | 0.72 | USP2 (0.32) | — | |
| SCHEMBL131576 | 0.71 | MEN1 (0.31) | MEN1HTTKMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2023-05-23 | — | — | US | disclosed |
| US-20200325161-A1 | HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS | GUANGDONG NEWOPP BIOPHARMACEUTICALS CO., LTD. (CN) | 2020-10-15 | — | — | US | disclosed |
| EP-2298778-A1 | IMIDAZOTHIAZOLE DERIVATIVE HAVING 4,7-DIAZASPIROÝ2.5¨OCTANE RING STRUCTURE | Daiichi Sankyo Company, Limited (JP) | 2011-03-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655260-B2 | Heterocyclic compounds as arginase inhibitors | ARG1, ARG2, PRMT1 | MEN1 1812/4885HTT 2416/4885KMT2A 2531/4885 |
| US-20200325161-A1 | HETEROCYCLIC COMPOUNDS AS ARGINASE INHIBITORS | ARG1, ARG2, PRMT1 | MEN1 1812/4885HTT 2416/4885KMT2A 2531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.